Journal article
Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation : Results at 2 years
Transplantation, Vol.72(2), pp.245-250
2001
DOI: 10.1097/00007890-200107270-00014
PMID: 11477347
Abstract
Background. A previous report described the 1-year results of a prospective, randomized trial designed to investigate the optimal combination of immunosuppressants in kidney transplantation. Recipients of first cadaveric kidney allografts were treated with tacrolimus+mycophenolate mofetil (MMF), cyclosporine oral solution (modified) (CsA)+MMF, or tacrolimus+azathioprine (AZA). Results at 1 year revealed that optimal efficacy and safety were achieved with a regimen containing tacrolimus+MMF. The present report describes results at 2 years. Methods. Two hundred twenty-three recipients of first cadaveric kidney allografts were randomized to receive tacrolimus+MMF, CsA+MMF, or tacrolimus+AZA. All regimens contained corticosteroids, and antibody induction was used only in patients who experienced delayed graft function. Patients were followed up for 2 years. Results. The results at 2 years corroborate and extend the findings of the previous report. Patients randomized to either treatment arm containing tacrolimus experienced improved kidney function. New-onset insulin dependence remained in four, three, and four patients in the tacrolimus+MMF, CsA+MMF, and tacrolimus+AZA treatment arms, respectively. Furthermore, patients with delayed graft function/acute tubular necrosis who were treated with tacrolimus+MMF experienced a 23% increase in allograft survival compared with patients receiving CsA+MMF (P=0.06). Patients randomized to tacrolimus+MMF received significantly lower doses of MMF compared with those administered CsA+MMF. Conclusions. All three immunosuppressive regimens provided excellent safety and efficacy. However, the best results overall were achieved with tacrolimus+MMF. The combination may provide particular benefit to kidney allograft recipients who develop delayed graft function/acute tubular necrosis. Renal function at 2 years was better in the tacrolimus treatment groups compared with the CsA group.
Details
- Title: Subtitle
- Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation : Results at 2 years
- Creators
- Nasimul AHSAN - Milton S. Hershey Medical Center, Hershey, Pennsylvania 17104-1696, United StatesChristopher JOHNSON - Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United StatesJohn SORENSEN - Latter Day Saints Hospital, Salt Lake City, Utah 84103, United StatesLaura MULLOY - Medical College of Georgia, Augusta, Georgia 30912, United StatesJimmy LIGHT - Washington Hospital Medical Center, Washington, DC 20010, United StatesClaudia CORWIN - University of Iowa, Iowa City, Iowa 52242-1086, United StatesGabriel DANOVITCH - University of California at Los Angeles, Los Angeles, California 90024-1681, United StatesMichael WACHS - University of Colorado, Denver, Colorado 80262, United StatesPaul VANVELDHUISEN - The EMMES Corporation, Potomac, Maryland 20854, United StatesKim SALM - Fujisawa Healthcare, Inc., Deerfield, Illinois 60015, United StatesDiane TOLZMAN - Fujisawa Healthcare, Inc., Deerfield, Illinois 60015, United StatesWilliam E FITZSIMMONS - Fujisawa Healthcare, Inc., Deerfield, Illinois 60015, United StatesThomas GONWA - Baylor University Medical Center, Dallas, Texas 75246, CanadaPhilip HALLORAN - University of Alberta, Edmonton, Alberta, T6G 2R8, CanadaMark STEGALL - University of Colorado, Denver, Colorado 80262, United StatesMark HARDY - Columbia Presbyterian, New York, New York 10032, United StatesRobert METZGER - Translife, Orlando, Florida 32804, United StatesCharles III SHIELD - Via Christ Medical Center, Wichita, Kansas 67214-3882, United StatesLeslie ROCHER - William Beaumont Hospital, Royal Oak, Michigan 48073, United StatesJohn SCANDLING - Stanford University, Palo Alto, California 94305-5342, United States
- Resource Type
- Journal article
- Publication Details
- Transplantation, Vol.72(2), pp.245-250
- DOI
- 10.1097/00007890-200107270-00014
- PMID
- 11477347
- NLM abbreviation
- Transplantation
- ISSN
- 0041-1337
- eISSN
- 1534-6080
- Publisher
- Lippincott
- Language
- English
- Date published
- 2001
- Academic Unit
- Pulmonary, Critical Care, and Occupational Medicine; Occupational and Environmental Health; Internal Medicine
- Record Identifier
- 9984094875202771
Metrics
12 Record Views